## Travis S Hughes

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5155019/publications.pdf

Version: 2024-02-01

471061 794141 1,919 19 17 19 citations h-index g-index papers 28 28 28 3485 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Regulation of circadian behaviour and metabolism by synthetic REV-ERB agonists. Nature, 2012, 485, 62-68.	13.7	638
2	Nuclear Receptors and Their Selective Pharmacologic Modulators. Pharmacological Reviews, 2013, 65, 710-778.	7.1	207
3	An alternate binding site for PPARγ ligands. Nature Communications, 2014, 5, 3571.	5.8	148
4	Ligand and Receptor Dynamics Contribute to the Mechanism of Graded PPARÎ <sup>3</sup> Agonism. Structure, 2012, 20, 139-150.	1.6	133
5	Resveratrol modulates the inflammatory response via an estrogen receptor-signal integration network. ELife, 2014, 3, e02057.	2.8	113
6	Structural mechanism for signal transduction in RXR nuclear receptor heterodimers. Nature Communications, 2015, 6, 8013.	5.8	101
7	Pharmacological repression of PPARÎ <sup>3</sup> promotes osteogenesis. Nature Communications, 2015, 6, 7443.	5.8	99
8	Ligand-binding dynamics rewire cellular signaling via estrogen receptor-α. Nature Chemical Biology, 2013, 9, 326-332.	3.9	53
9	Defining a conformational ensemble that directs activation of PPAR $\hat{I}^3$ . Nature Communications, 2018, 9, 1794.	5.8	53
10	Cooperative cobinding of synthetic and natural ligands to the nuclear receptor PPAR $\hat{I}^3$ . ELife, 2018, 7, .	2.8	53
11	PEGylation of brainâ€derived neurotrophic factor for preserved biological activity and enhanced spinal cord distribution. Journal of Biomedical Materials Research - Part A, 2009, 91A, 719-729.	2.1	47
12	Synergistic Regulation of Coregulator/Nuclear Receptor Interaction by Ligand and DNA. Structure, 2017, 25, 1506-1518.e4.	1.6	45
13	A structural mechanism for directing corepressor-selective inverse agonism of PPARγ. Nature Communications, 2018, 9, 4687.	5.8	38
14	Defining a Canonical Ligand-Binding Pocket in the Orphan Nuclear Receptor Nurr1. Structure, 2019, 27, 66-77.e5.	1.6	37
15	Probing the Complex Binding Modes of the PPARγ Partial Agonist  2-Chloro- <i>N</i> -(3-chloro-4-((5-chlorobenzo[ <i>d</i> )]thiazol-2-yl)thio)phenyl)-4-(trifluoromethyl)benzenesulfor (T2384) to Orthosteric and Allosteric Sites with NMR Spectroscopy. Journal of Medicinal Chemistry, 2016. 59. 10335-10341.	namjde 2.9	24
16	Structure of REV-ERBÎ <sup>2</sup> Ligand-binding Domain Bound to a Porphyrin Antagonist. Journal of Biological Chemistry, 2014, 289, 20054-20066.	1.6	22
17	Definition of functionally and structurally distinct repressive states in the nuclear receptor PPARÎ <sup>3</sup> . Nature Communications, 2019, 10, 5825.	5.8	20
18	Immunogenicity of intrathecal plasmid gene delivery: cytokine release and effects on transgene expression. Journal of Gene Medicine, 2009, 11, 782-790.	1.4	19

## TRAVIS S HUGHES

#	Article	IF	CITATIONS
19	Deconvolution of Complex 1D NMR Spectra Using Objective Model Selection. PLoS ONE, 2015, 10, e0134474.	1.1	15